DaVita (NYSE: DVA) is one of the largest providers of kidney dialysis services in the United States. Shares recently traded around $114 per share, giving the company a market capitalization of roughly $8.0B.
DaVita’s stock has pulled back meaningfully over the past year, while ownership remains highly concentrated. Looking at who owns DaVita and how insiders have been trading helps show how large shareholders and company leadership appear to be positioning around the stock today.
Who Are DaVita’s Top Shareholders?
DaVita’s shareholder base is anchored by a long-time controlling owner, with the remainder spread across large passive institutions and a smaller group of active managers. This structure can add stability, but it also means changes by a few holders can have an outsized impact.
- Berkshire Hathaway Inc.: 31,759,065 shares (44.98%), ~$3.61B value. Reduced its stake by 401,514 shares (1.25%).
- The Vanguard Group, Inc.: 4,209,656 shares (5.96%), ~$478.3M value. Cut 518,535 shares (10.97%).
- BlackRock Institutional Trust Company, N.A.: 2,396,106 shares (3.39%), ~$272.2M value. Reduced by 242,287 shares (9.18%).
- Weschler (R Ted): 2,183,180 shares (3.09%), ~$248.0M value. No reported change.
- State Street Investment Management (US): 1,834,829 shares (2.60%), ~$208.5M value. Reduced by 258,505 shares (12.35%).
- Invesco Capital Management LLC: 1,399,422 shares (1.98%), ~$159.0M value. Added 57,018 shares (4.25%).
- Gates Capital Management, Inc.: 1,190,383 shares (1.69%), ~$135.2M value. Added 91,403 shares (8.32%).
- Dimensional Fund Advisors, L.P.: 1,085,593 shares (1.54%), ~$123.3M value. Added 88,061 shares (8.83%).
- Geode Capital Management, L.L.C.: 1,023,374 shares (1.45%), ~$116.3M value. Reduced by 86,311 shares (7.78%).
- LSV Asset Management: 927,029 shares (1.31%), ~$105.3M value. Reduced by 13,700 shares (1.46%).
For investors, Berkshire Hathaway’s continued ownership keeps DaVita tightly controlled despite modest trimming, while mixed moves from passive and active managers suggest differing views on valuation and long term risk.
Hedge Fund Highlights
One notable move last quarter came from Jane Street Group, founded by Robert Granieri, which sharply increased its DaVita position. The firm boosted its stake by over 2,100%, now holding roughly $33M value, suggesting it may be leaning into the stock’s pullback as a potential opportunity.
Another increase came from Deerfield Management, led by James Flynn, which lifted its DaVita stake by nearly 784% to about $2.5M value. Given Deerfield’s healthcare focus, it appears the firm may be growing more comfortable with DaVita’s long term cash flow profile.
Citadel Advisors, founded by Ken Griffin, also increased exposure, raising its position by roughly 213% to nearly $60M value. The size of the increase suggests Citadel may be positioning around valuation or volatility rather than making a purely directional bet.
Meanwhile, Tudor Investment Corp, founded by Paul Tudor Jones, boosted its stake by about 156%, ending the quarter with roughly $14M value invested. While still modest in size, the increase points to selective interest following the stock’s decline.
For investors, hedge fund activity appears selective rather than one-sided, with some firms stepping in while others remain cautious.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
DaVita’s Recent Insider Trades
Insider trades can provide additional context on how executives and directors may be managing personal exposure to the stock. Recent filings show a mix of selling activity and equity-related entries.
- James O. Hearty (Officer): Sold shares totaling ~$640k near $118; acquired 5,875 shares at ~$109.
- Javier J. Rodriguez (Officer and Director): Sold 5,165 shares for ~$628k at $121.55.
- David Paul Maughan (Officer): Sold 7,501 shares for ~$977k at $130.16.
- Berkshire Hathaway Inc. (Beneficial Owner): Sold 401,514 shares for ~$54.3M at $135.36.
- Multiple Directors: Recorded 411 shares each at $0 on 11/14/25, with similar smaller entries earlier in the year.
For investors, insider activity appears tilted toward selling and equity-related entries, and while intent cannot be confirmed, it looks like leadership is managing exposure rather than signaling strong conviction at current prices.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
DaVita remains a tightly controlled company, anchored by Berkshire Hathaway’s large stake despite modest trimming. Outside of that position, institutional ownership has shifted gradually, with passive funds reducing exposure and select hedge funds adding.
Insider transactions lean cautious, and hedge fund positioning appears targeted rather than aggressive. For investors, the overall picture suggests growing interest after the stock’s pullback, but positioning remains measured as the market reassesses DaVita’s long term value and risk profile.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
